| 1 |
Nutten S. Atopic dermatitis: global epidemiology and risk factors[J]. Ann Nutr Metab, 2015, 66(): 8-16.
|
| 2 |
Avena-Woods C. Overview of atopic dermatitis[J]. Am J Manag Care, 2017, 23(8): S115-S123.
|
| 3 |
Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications[J]. Allergy Asthma Proc, 2019, 40(2): 84-92.
|
| 4 |
Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects[J]. Drugs, 2017, 77(5): 521-546.
|
| 5 |
Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology[J]. Front Immunol, 2019, 10: 2847.
|
| 6 |
Gündüz Ö. JAK/STAT pathway modulation: does it work in dermatology?[J]. Dermatol Ther, 2019, 32(3): e12903.
|
| 7 |
Weidinger S, Novak N. Atopic dermatitis[J]. Lancet, 2016, 387(10023): 1109-1122.
|
| 8 |
Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis[J]. J Dermatolog Treat, 2020, 31(1): 33-40.
|
| 9 |
王学川, 李霄, 梁承远. 基于JAK-STAT信号通路的药物研究进展[J]. 陕西科技大学学报, 2019, 37(6): 79-86.
|
| 10 |
Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases[J]. Nat Rev Drug Discov, 2017, 17(1): 78.
|
| 11 |
Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream[J]. J Allergy Clin Immunol, 2020, 145(2): 572-582.
|
| 12 |
Bertsias G. Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors[J]. Mediterr J Rheumatol, 2020, 31(): 105-111.
|
| 13 |
Duggan S, Keam SJ. Upadacitinib: first approval[J]. Drugs, 2019, 79(16): 1819-1828.
|
| 14 |
Sonthalia S, Aggarwal P. Oral tofacitinib: contemporary appraisal of its role in dermatology[J]. Indian Dermatol Online J, 2019, 10(5): 503-518.
|
| 15 |
Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase Ⅱa randomized trial[J]. Br J Dermatol, 2016, 175(5): 902-911.
|
| 16 |
Markham A. Baricitinib: first global approval[J]. Drugs, 2017, 77(6): 697-704.
|
| 17 |
Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study[J]. J Am Acad Dermatol, 2019, 80(4): 913-921.e9.
|
| 18 |
Ajayi S, Becker H, Reinhardt H, et al. Ruxolitinib[J]. Recent Results Cancer Res, 2018, 212: 119-132.
|
| 19 |
Dhillon S. Delgocitinib: first approval[J]. Drugs, 2020, 80(6): 609-615.
|
| 20 |
Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo[J]. Inflamm Res, 2015, 64(1): 41-51.
|
| 21 |
Nakagawa H, Nemoto O, Igarashi A, et al. Efficacy and safety of topical JTE-052, a janus kinase inhibitor, in japanese adult patients with moderate-to-severe atopic dermatitis: a phase Ⅱ, multicentre, randomized, vehicle-controlled clinical study[J]. Br J Dermatol, 2018, 178(2): 424-432.
|
| 22 |
Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)[J]. BMC Rheumatol, 2018, 2: 23.
|
| 23 |
Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial[J]. J Allergy Clin Immunol, 2020, 145(3): 877-884.
|
| 24 |
Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib[J]. Am J Clin Dermatol, 2020, 21(6): 783-798.
|
| 25 |
Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial[J]. JAMA Dermatol, 2020, 156(8): 863-873.
|
), Mei-liang GUO, Wan-wen LIU, Hui DENG(